143 related articles for article (PubMed ID: 17086938)
1. Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity.
Moore MC
Curr Opin Investig Drugs; 2006 Oct; 7(10):924-35. PubMed ID: 17086938
[TBL] [Abstract][Full Text] [Related]
2. Exenatide. Amylin/Eli Lilly.
Giannoukakis N
Curr Opin Investig Drugs; 2003 Apr; 4(4):459-65. PubMed ID: 12808888
[TBL] [Abstract][Full Text] [Related]
3. Tagatose, a new antidiabetic and obesity control drug.
Lu Y; Levin GV; Donner TW
Diabetes Obes Metab; 2008 Feb; 10(2):109-34. PubMed ID: 17941870
[TBL] [Abstract][Full Text] [Related]
4. Taranabant, a novel cannabinoid type 1 receptor inverse agonist.
Fremming BA; Boyd ST
Curr Opin Investig Drugs; 2008 Oct; 9(10):1116-29. PubMed ID: 18821475
[TBL] [Abstract][Full Text] [Related]
5. American Diabetes Association--69th Scientific sessions. Obesity management and treatment of type 2 diabetes: Part 1.
Kouremenou C
IDrugs; 2009 Aug; 12(8):463-4. PubMed ID: 19629873
[No Abstract] [Full Text] [Related]
6. Tagatose: from a sweetener to a new diabetic medication?
Espinosa I; Fogelfeld L
Expert Opin Investig Drugs; 2010 Feb; 19(2):285-94. PubMed ID: 20050825
[TBL] [Abstract][Full Text] [Related]
7. NN-414. Novo Nordisk.
Choi JK
Curr Opin Investig Drugs; 2003 Apr; 4(4):455-8. PubMed ID: 12808887
[TBL] [Abstract][Full Text] [Related]
8. MK-767. Kyorin/Banyu/Merck.
Calkin AC; Thomas MC; Cooper ME
Curr Opin Investig Drugs; 2003 Apr; 4(4):444-8. PubMed ID: 12808885
[TBL] [Abstract][Full Text] [Related]
9. Insulin detemir. Novo Nordisk.
Barlocco D
Curr Opin Investig Drugs; 2003 Apr; 4(4):449-54. PubMed ID: 12808886
[TBL] [Abstract][Full Text] [Related]
10. New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity.
Taylor JR; Dietrich E; Powell JG
Clin Ther; 2013 Jan; 35(1):A3-17. PubMed ID: 23328274
[TBL] [Abstract][Full Text] [Related]
11. Cetilistat, a new lipase inhibitor for the treatment of obesity.
Padwal R
Curr Opin Investig Drugs; 2008 Apr; 9(4):414-21. PubMed ID: 18393108
[TBL] [Abstract][Full Text] [Related]
12. Managlinat dialanetil, a fructose-1,6-bisphosphatase inhibitor for the treatment of type 2 diabetes.
Wang Y; Tomlinson B
Curr Opin Investig Drugs; 2007 Oct; 8(10):849-58. PubMed ID: 17907062
[TBL] [Abstract][Full Text] [Related]
13. CLX-0901 (Calyx Therapeutics).
Barlocco D
Curr Opin Investig Drugs; 2001 May; 2(5):650-3. PubMed ID: 11569941
[TBL] [Abstract][Full Text] [Related]
14. Orally bioavailable beta 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes.
Hu B; Jennings LL
Prog Med Chem; 2003; 41():167-94. PubMed ID: 12774694
[No Abstract] [Full Text] [Related]
15. Insulin glulisine. Aventis Pharma.
Barlocco D
Curr Opin Investig Drugs; 2003 Oct; 4(10):1240-4. PubMed ID: 14649217
[TBL] [Abstract][Full Text] [Related]
16. New options for drug treatment of obesity in patients with Type 2 diabetes.
Kennedy RL; Khoo EY
Diabet Med; 2005 Sep; 22 Suppl 4():23-6. PubMed ID: 16109016
[No Abstract] [Full Text] [Related]
17. All in one: Researchers create combination drugs for diabetes and obesity.
Chakradhar S
Nat Med; 2016 Jul; 22(7):694-6. PubMed ID: 27387879
[No Abstract] [Full Text] [Related]
18. SomatoKine. Insmed.
Norman P
Curr Opin Investig Drugs; 2003 Apr; 4(4):466-71. PubMed ID: 12808889
[TBL] [Abstract][Full Text] [Related]
19. The role of pramlintide for weight loss.
Dunican KC; Adams NM; Desilets AR
Ann Pharmacother; 2010 Mar; 44(3):538-45. PubMed ID: 20164472
[TBL] [Abstract][Full Text] [Related]
20. Eligen insulin--a system for the oral delivery of insulin for diabetes.
Hoffman A; Qadri B
IDrugs; 2008 Jun; 11(6):433-41. PubMed ID: 18509785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
